Vaxart, Inc., founded in 2004 by Sean Tucker and headquartered in South San Francisco, California, is a clinical-stage biotechnology company. Its core mission is to revolutionize vaccine administration through the development of oral recombinant protein vaccines using its proprietary oral vaccine platform. The company's product pipeline includes vaccines for norovirus, seasonal influenza, and respiratory syncytial virus (RSV), with several candidates currently in Phase II clinical trials. Vaxart aims to provide more accessible and effective vaccination methods by targeting mucosal immunity.

Notable figures associated with Vaxart include CEO Steven Lo. The company is publicly traded on Nasdaq under the ticker VXRT. Vaxart has achieved significant milestones, such as advancing its COVID-19 oral vaccine candidate to Phase II trials. Despite reporting a net loss of $82.4 million in 2023, Vaxart's innovative approach has the potential to transform vaccine delivery and improve global health outcomes by making vaccines easier to administer and more effective at preventing infections.